Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;12(5):848-850.
doi: 10.1016/j.jgo.2021.03.003. Epub 2021 Mar 5.

The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer

Affiliations
Comment

The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer

Anna Rachelle Mislang et al. J Geriatr Oncol. 2021 Jun.
No abstract available

Keywords: COVID-19; Cancer; Older patients; SIOG; Vaccine.

PubMed Disclaimer

Comment on

References

    1. Battisti N.M.L., Mislang A.R., Cooper L., O’Donovan A., Audisio R.A., Cheung K.L., et al. Adapting care for older cancer patients during the COVID-19 pandemic: recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 working group. J Geriatr Oncol. 2020;11(8):1190–1198. - PMC - PubMed
    1. Organization WH Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 2021. 2021. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVI... Available from:
    1. Helfand B.K.I., Webb M., Gartaganis S.L., Fuller L., Kwon C.S., Inouye S.K. The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019-missing the target. JAMA Intern Med. 2020;180(11):1546–1549. - PMC - PubMed
    1. Crooke S.N., Ovsyannikova I.G., Poland G.A., Kennedy R.B. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25. - PMC - PubMed
    1. Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993. - PMC - PubMed

Substances